AI helper
The U. S. Department of State (DOS), Bureau of Global Health Security and Diplomacy (GHSD), is seeking proposals for an all-inclusive molecular diagnostic laboratory service for supported countries. This contract aims to procure directly from U. S. manufacturers, defined as companies incorporated in the U. S. or U. S. subsidiaries with majority U. S. -based R&D and manufacturing. The service will cover HIV viral load and early infant diagnosis, tuberculosis diagnosis and drug-resistant testing, and prepositioned testing for global health security pathogens like Ebola. The model is an all-inclusive per-test service, meaning the contractor is responsible for instruments, reagents, consumables, international freight, customs clearance, in-country transportation, cold chain, maintenance, operator training, data connectivity, regulatory compliance, and supply chain management. No separate charges are permitted beyond the all-inclusive per-test price. Data connectivity for automated transmission of operational, supply chain, and epidemiologic data is a core obligation. Eligible platforms must be closed-system instruments with regulatory clearance from a stringent regulatory authority (SRA), such as the U. S. FDA. Platforms requiring manual data entry or transmitting data through servers in restricted countries are ineligible. The estimated annual spend is approximately $160 million, with a range of $120 million to $220 million. The award structure will accommodate multiple contracted countries, platforms, and disease areas, with per-test prices being a critical factor in awards. The period of performance is to be determined. Services will be performed at designated laboratory sites in contracted countries, including national, regional, and district laboratories, as well as near-patient testing sites. The contractor must demonstrate an incountry operational presence in Sub-Saharan Africa, cold chain and last-mile distribution capability, an ISO **** quality management system, and instrument connectivity and data interoperability. Past performance in all-inclusive or service-based supply models and financial stability are evaluated criteria. The contractor must submit a country site activation plan within 30 days of award or direction to add a country, including site readiness assessments, regulatory status, logistics plans, and staffing. A GHS surge readiness plan is also required.
The bid notice does not explicitly state a delivery deadline for the services or goods. The period of performance is TBD.
The bid notice does not specify payment terms.
The bid notice does not specify warranty terms.
The bid notice states that The government anticipates the allinclusive price per test will be a critical factor in determining the tests and countries for which an offer is awarded.
The bid notice outlines mandatory eligibility criteria including stringent regulatory authority (SRA) approval for each instrument platform and assay, a closed-system molecular diagnostic platform, demonstrated in-country operational presence in Sub-Saharan Africa, capability in cold chain and last-mile distribution, an ISO **** quality management system, and instrument connectivity and data interoperability capability.
The bid notice does not specify penalties.
The bid notice does not mention a site visit.
The bid notice does not mention sample submission.
The bid notice does not specify a challenge deadline.
The bid notice states that any offeror that fails any single mandatory criterion is ineligible for award and will not advance to technical evaluation.
The estimated annual spend for this contract is forecasted to be approximately $160 million, within a range of $120 million to $220 million annually.
